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Abstract
Background: 17alpha-hydroxylase/17, 20-lyase encoded by CYP17 is the key enzyme in androgen
biosynthesis pathway. Previous studies demonstrated the accentuation of the enzyme in patients
with polycystic ovary syndrome (PCOS) was the most important mechanism of androgen excess.
We chose CYP17 as the therapeutic target, trying to suppress the activity of 17alpha-hydroxylase/
17, 20-lyase and inhibit androgen biosynthesis by silencing the expression of CYP17 in the rat ovary.
Methods: Three CYP17-targeting and one negative control oligonucleotides were designed and
used in the present study. The silence efficiency of lentivirus shRNA was assessed by qRT-PCR,
Western blotting and hormone assay. After subcapsular injection of lentivirus shRNA in rat ovary,
the delivery efficiency was evaluated by GFP fluorescence and qPCR. Total RNA was extracted
from rat ovary for CYP17 mRNA determination and rat serum was collected for hormone
measurement.
Results: In total, three CYP17-targeting lentivirus shRNAs were synthesized. The results showed
that all of them had a silencing effect on CYP17 mRNA and protein. Moreover, androstenedione
secreted by rat theca interstitial cells (TIC) in the RNAi group declined significantly compared with
that in the control group. Two weeks after rat ovarian subcapsular injection of chosen CYP17
shRNA, the GFP fluorescence of frozen ovarian sections could be seen clearly under fluorescence
microscope. It also showed that the GFP DNA level increased significantly, and its relative
expression level was 7.42 times higher than that in the control group. Simultaneously, shRNA
treatment significantly decreased CYP17 mRNA and protein levels at 61% and 54%, respectively.
Hormone assay showed that all the levels of androstenedione, 17-hydroxyprogesterone and
testosterone declined to a certain degree, but progesterone levels declined significantly.
Conclusion: The present study proves for the first time that ovarian androgen biosynthesis can
be inhibited by silencing CYP17 expression. It may provide a novel strategy for therapy of
hyperandrogenism diseases, and also set an example for the use of RNAi technology in endocrine
diseases.
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Background
Polycystic ovary syndrome (PCOS) is one of the most
common gynecological endocrine diseases, which has an
incidence rate of 5–10% in women of reproductive age.
Hyperandrogenism is closely associated with PCOS, and
is regarded as the most important presentation of PCOS.
About 60–80% of patients with PCOS have signs of
hyperandrogenism, such as hypertrichosis, acne and bald-
ness [1-3]. Additionally, the patient with PCOS often
presents with anovulation which is associated with follic-
ular dysfunction induced by hyperandrogenism [4].
Androgen excess can also impair glucose tolerance, lead-
ing to insulin resistance, and causing a series of metabolic
diseases [5,6]. Although some anti-androgen drugs (such
as cyproterone metformin), single or in combination,
have been used to treat the patient with PCOS, but thera-
peutic effects are unsatisfied and side effects are still under
concerns [7,8].
17alpha-hydroxylase/17, 20-lyase is the key enzyme in
androgen biosynthesis pathways. It resides in the ovary
and the adrenal gland and is encoded by CYP17. This
enzyme has double activities of 17alpha-hydroxylase and
17, 20-lyase, which are necessary for the conversion of
pregnenolone to 17-hydroxypregnenolone and dehydroe-
piandrosterone, and for the conversion of progesterone to
17-hydroxyprogesterone and androstenedione. Several
studies have demonstrated the accentuation of 17alpha-
hydroxylase/17, 20-lyase as an important mechanism of
androgen excess [9,10], in patients with PCOS. It was con-
firmed by an in vitro study of ovarian theca cells from a
patient with PCOS, that the accentuation of 17alpha-
hydroxylase/17, 20-lyase was caused by augmentation of
CYP 17 at transcriptional levels [11,12].
RNA interference (RNAi) as an emerging biological tech-
nology for silencing gene expression has become a poten-
tially powerful tool for therapy of clinical diseases. At
present, outstanding progress has been made using RNAi
in the therapy of tumors [13,14], viral infections [15-17]
and genetic diseases [18-20]. It was reported that silencing
Fas expression with RNAi holds therapeutic promise to
prevent liver fulminant hepatitis [15]. Study also showed
that silencing mutant SOD1 using RNAi could protect
against neuro-degeneration and extend survival in an ALS
model [18]. In our study, we chose CYP17 as the thera-
peutic target, trying to partly suppress the activity of
17alpha-hydroxylase/17, 20-lyase and inhibit rat andro-
gen biosynthesis by silencing the expression of CYP17. We
hope our research can provide a new direction for treat-
ment of hyperandrogenism in the future.
Methods
Animals
Eighteen female Sprague-Dawley rats, aged two months
and weighing 200 g, were raised in an animal laboratory
of specific pathogen-free grade, with free access to food
and water. Our study was approved by the ethics commit-
tee of the First Affiliated Hospital of Sun Yat-sen Univer-
sity. The animals were sacrificed by a lethal dose of chloral
hydrate. The ovaries were removed for in vitro culture of
theca interstitial cells (TIC) and preparation of frozen
ovarian sections. Serum samples were stored at -20°C
until use for hormone assays. During in vivo studies, the
rats were divided into three groups of 6 rats: CYP17 RNAi
group, negative control group, and blank control group.
Design and construction of lenivirus CYP17 shRNA
Three CYP17-targeting oligonucleotides were designed,
and another one was the negative control (Fig. 1). The
stem loop DNA nucleotides were synthesized, and cloned
into pGL-Lentivirus vectors by Genechem Co., Ltd
(Shanghai, China). Lentivirus particles were prepared by
Lentivirus Expression Systems (Shanghai, China) and
viral titers were 5 × 108 transducing units/ml.
Rat ovarian TIC isolation and culture
The rat ovarian TIC was isolated and purified with discon-
tinuous percoll gradient centrifugation as described previ-
ously [21]. The TIC was cultured in a 12-well plate
(Falcon, Becton Dickinson Labware, Lincoln Park, NJ) (1
× 106 cells/well). Each experiment was performed in a
minimum of triplicate wells, and at least three experi-
ments were performed in qRT-PCR, Western-blot and hor-
mone assays to verify the silencing effect of constructed
CYP17shRNAs in vitro. The culture medium was
McCoy's5a (Invitrogen, CA) with supplementation of L-
glutamine, BSA (1 mg/ml), penicillin (10000 IU/ml), and
streptomycin (10000 mg/ml). Incubation was carried out
at 37°C in humidified air with 5% CO2 for 5 or 7 days.
Quantitative PCR
To analyze CYP17 mRNA levels, total RNA was extracted
from cultured TIC or rat ovarian tissue, and used as a tem-
plate for cDNA synthesis using oligo (dT) primers with the
superscriptIII kit (Invitrogen, CA). Total DNA was
extracted from the rat ovary to assess GFP DNA levels.
Real-time quantitative PCR was performed using the ABI
Prism 7500 detection system with SYBR green DNA detec-
tion kit (Applera, NY). The expression levels of house-
keeping genes encoding β-actin were also quantified, and
used for normalization. The PCR primers for CYP17 were
as follows: Forward primers 5'-GGCCTTTGCAGATGCT-
GGTA-3', reverse primer 5'-GGAAAAGGTGCTGAACAC-
CAA-3'. The PCR primers for β-actin were as follows:
Forward primers 5'-GCTGCTGACCCCCACTGAT-3',
reverse primer 5'-GCCACTGCCGGACAACTC-3'. TheReproductive Biology and Endocrinology 2009, 7:73 http://www.rbej.com/content/7/1/73
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reactive condition of CYP17 PCR was 94°C 3 min, 94°C
30 sec, 55°C 60 sec, 10 cycles, then 94°C 30 sec, 55°C 60
sec, 30 cycles. The PCR primers for GFP were as follows:
Forward primers TGCTTCAGCCGCTACCC, reverse
primer CTTGCCGTAGTTCCACTTGA. The reactive condi-
tion of GFP PCR was 95°C 15 sec, 95°C 5 sec, 60°C 30
sec, 45 cycles in total.
Western-blotting
Protein samples were extracted from cultured cells using
cell lysis buffers. Each sample of protein (15 μg) was frac-
tionated by SDS-PAGE. Following transfer onto a nitrocel-
lulose membrane, blots were probed with a goat
polyclonal antibody to CYP17 (1:1000, Santa Cruz Bio-
technology, CA), and a rabbit polyclonal antibody to β-
actin (1:1000, Santa Cruz Biotechnology). Blots were then
incubated with anti-goat and anti-rabbit secondary anti-
bodies (1:5000) tagged with horseradish peroxidase. All
blots were visualized with Enhanced Chemiluminescence
(Amersham Biosciences, Uppsala, Sweden) and analyzed
by Image J Software (NIH, Maryland).
Hormone assay
After collection, culture medium and rat serum samples
were stored at -20°C for hormone measurement. Andros-
tenedione and 17-hydroxyprogesterone levels were meas-
ured using an enzyme-linked immunosorbent assay kit
(Diagnostic System Laboratories, TX). The detection limit
of the assay was 0.05–10 ng/ml. The intra- and inter-assay
coefficients of variation were 5 and 8.0%, respectively.
Testosterone and progesterone levels were measured
using electrochemiluminescence immunoassays on an
Sequences of lentivirus CYP17shRNAs and NC shRNA Figure 1
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Elecsys E-170 analyzer (Roche Diagnostics Systems, Basel,
Switzerland). The sensitivity of the method defined as the
detectable concentration was 0.15 pg/ml.
Lentivirus injection
Lentivirus was injected subcapularly into the rat ovary
with a 10 μl-syringe (Gaoge, Shanghai, China). Needle
was injected slowly and held in place for 5 minutes. Each
ovary was injected twice on different sites with 10 μl each
time. In total, each rat was injected with 40 μl of lentivirus
(Fig. 2).
Fluorescence imaging
Two weeks after lentivirus injection, rat ovaries were
removed and cut into 5 μm in thickness of serial sections.
GFP fluorescence was observed under microscope using a
fluorescence light source and a 485-nm filter (Leica, Ger-
many).
Statistics
Data were expressed as mean ± SD and analyzed using
ANOVA by SPSS 11.0 software (SPSS Inc. Illinois). p ≤
0.05 was considered statistically significant.
Results
Screen of lentivirus CYP17 shRNA in vitro
Three constructed lentivirus shRNAs, targeting different
sites of CYP17, were transduced into TIC, cultured in
vitro, with a multiplicity of infection of 10 transducing
units/ml. Negative and blank control groups were estab-
lished in the meantime. Seventy-two hours after transduc-
tion GFP fluorescence could clearly be seen under
fluorescence microscope (Fig 3A). Five days after trans-
duction, cells were harvested and total RNA was extracted
for CYP17 mRNA measurement. It showed that all three
constructed lentivirus shRNAs had silencing effects on
CYP17, and their silence efficiency was 65.5%, 73.7% and
77.4%, respectively (Fig 3B). Seven days after transduc-
tion, total protein was extracted for CYP17 protein meas-
urement. Results showed that three constructed lentivirus
shRNAs also had silencing effects on CYP17 protein
expression, and their silence efficiencies were 50%, 50%
and 61%, respectively (Fig. 3C).
For further confirmation of the biological effect of con-
structed lentivirus CYP17 shRNAs, culture medium was
collected for the measurement of androstenedione levels
on days 6, 8, and 10 of lentivirus infection (Table 1). On
day 6, androstenedione in RNAi group declined slightly,
but it declined significantly on day 8. Although andros-
tenedione in the 2# group on day 10 stepped up slightly,
compared with day 8, it actually decreased more pro-
foundly compared with the control groups.
Through in vitro experiments, we relatively confirmed the
silencing effects of constructed lentivirus shRNAs on
CYP17 in mRNA, protein and hormone levels. The results
showed that all three constructed lentivirus shRNAs had
silencing effects on CYP17. We finally chose lentivirus
CYP17 shRNA2# for the in vivo animal study because of
its consistent effect.
Delivery efficiency measurement
Two weeks after rat ovarian subcapsular injection of lenti-
virus, animals were sacrificed. Ovarian tissues were
removed and frozen sections were prepared. The GFP flu-
orescence could clearly be seen under fluorescence micro-
scope (Fig. 4A). Ovarian total RNA was also extracted for
The surgical diagrams of rat ovarian subcapsular injection and the injection site was seen blue (as injection of mthylene blue) Figure 2
The surgical diagrams of rat ovarian subcapsular injection and the injection site was seen blue (as injection of 
mthylene blue). A, The rat ovary was presented before injection. B, Mthylene blue was subcapsularly injected into rat ovary. 
C, The rat ovary was presented after injection of mthylene blue.

 Reproductive Biology and Endocrinology 2009, 7:73 http://www.rbej.com/content/7/1/73
Page 5 of 8
(page number not for citation purposes)
The CYP17 silenced by lentivirus shRNAs in vitro Figure 3
The CYP17 silenced by lentivirus shRNAs in vitro. A, GFP fluorescence observed 72 hours after lentivirus transduction. 
B, Quantitative assay of CYP17 mRNA levels 5 days after lentivirus transduction from six different replicates. C, CYP17 pro-
tein levels 7 days after lentivirus transduction. D, Quantitative results of Western blotting images from three different repli-
cates. CON: Blank Control; NC: Negative Control: 1#: CYP17 shRNA1#; 2#: CYP17 shRNA2#; 3#: CYP17 shRNA3#. 
ANOVA, *P < 0.05 when compared with CON and NC groups. *ANOVA, P < 0.05, when compared with both CON and NC 
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GFP mRNA level measurement. It showed that the GFP
DNA level increased significantly, and its relative expres-
sion level was 7.42 times higher than that in the blank
control group (Fig. 4B). These results demonstrated that
the lentivirus had been successfully delivered to the ovar-
ian tissue by subcapsular injection.
CYP17 silence in vivo
Two weeks after lentivirus CYP17 shRNA2# injection,
total RNA of ovarian tissue was extracted for the measure-
ment of silence efficiency of lentivirus shRNA. When com-
pared with the blank control group, CYP17 mRNA levels
in the negative control group declined slightly. However,
CYP17 mRNA levels declined significantly in the RNAi
group with an average inhibition rate of 61% (Fig. 5).
Hormone assay results showed that all the levels of
androstenedione, 17-hydroxyprogesterone and testoster-
one declined to a certain degree, but with no statistical sig-
nificant differences. However, progesterone levels
declined significantly (Table 2).
Discussion
Androgen excess is the primary pathogenesis of PCOS, in
addition, the accentuation of 17alpha-hydroxylase/17,
20-lyase caused by transcriptional augmentation of
CYP17 is the most important mechanism [22]. For the
first time, we chose CYP17 as the therapeutic target using
RNAi technology, silencing the expression of CYP17, and
partly inhibiting the ovarian biosynthesis of androgen.
In our study, we constructed three lentivirus shRNAs tar-
geting CYP17. For confirmation of their effectiveness, we
Table 1: Comparison of androstenedione levels on different days after CYP17 shRNA 2# transduction, values are expressed as mean ± 
SD.









Day 6 0.33 ± 0.028 0.16 ± 0.022 0.15 ± 0.045
Day 8 0.15 ± 0.029 0.081 ± 0.0068 0.047 ± 0.016 *
Day 10 0.32 ± 0.068 0.19 ± 0.078 0.085 ± 0.0094 *
*ANOVA, P < 0.05, when compared with both CON and NC groups. CON: Blank Control; NC: Negative Control: 2#: CYP17 shRNA2#.
The delivery efficiency of lentivirus after ovarian capsular injection Figure 4
The delivery efficiency of lentivirus after ovarian capsular injection. A, The GFP fluorescence of frozen ovarian sec-
tions 2 weeks after lentivirus injection. B, Quantitative assay of relative expression level of GFP DNA 2 weeks after lentivirus 
injection from six different replicates. *Student's t test, P < 0.05, when compared with blank control group.Reproductive Biology and Endocrinology 2009, 7:73 http://www.rbej.com/content/7/1/73
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transduced lentivirus shRNAs into TIC cultured in vitro,
and proved that all three constructed lentivirus shRNAs
could silence the expression of CYP17 to different degrees.
Through collection of culture medium at different time
points for androstenedione determination, it was found
that androstenedione began decreasing on day 6, and
declined more profoundly on day 8 and day 10. The
results suggested that it may be a slow process for lentivi-
rus to integrate into the cellular genome to develop its
biological effect. The androstenedione level on day 10 was
slightly higher than those on day 6 and day 8, but andros-
tenedione levels in the negative control group on day 10
were also higher than those on days 6 and 8. The explana-
tion for this was that the cell number of TIC on day 10 was
increased, and so was the hormone secretion. However,
androstenedione still declined more significantly when
compared with negative and control groups.
During the in vivo study, we first studied the biological
effect of lentivirus CYP17 shRNA on the rat ovary using
ovarian subcapsular injection. This method was not only
less invasive to the ovary, but it also made lentivirus dis-
perse and sufficiently contact with the follicles, which was
beneficial for lentivirus to take effect. The fluorescence
and qPCR of GFP also confirmed that the injected lentivi-
rus was successfully delivered into the rat ovary. After
injection, CYP17 mRNA declined to a certain degree in the
negative control group, which may have been caused by
non-specific effects of shRNA. But in the RNAi group the
CYP17 mRNA was decreased more significantly, which
suggested the shRNA still had a specific silencing effect on
CYP17. Two weeks after lentivirus injection, all the levels
of androstenedione, 17-hydroxyprogesterone and testo-
sterone declined, but with no significant statistical differ-
ences. The possible reasons may be as follows: The dose of
injected lentivirus shRNA in vivo was low. It may need to
be increased for better silencing effect in vivo. In addition,
the small sample number was also a possible reason.
Noticeably, progesterone was also decreased, which was
similar to our previous study [23]. The possible explana-
tion for this is that the lenivirus shRNA may interfere with
the cholesterol uptake and metabolism of TIC, but this
notion needs further study to confirm.
Conclusion
According to our study, ovarian androgen biosynthesis
can be partly inhibited by silencing the expression of
CYP17. This may not only provide a new trend for the
therapy of hyperandrogenism diseases like PCOS, but also
set an example for the use of RNAi technology in endo-
crine diseases. However, there are some limits in our
study, such as the safety of lentivirus vectors and the com-
plication of surgical delivery. Moreover, the dose-effect
relationship of CYP17 silencing in vivo and its synthetic
effect on the metabolism of steroid hormones needs to be
further studied.
Abbreviations
PCOS: Polycystic Ovary Syndrome; RNAi: RNA interfer-
ence; TIC: theca interstitial cells.











Androstenedione 0.43 ± 0.19 0.94 ± 0.012 0.33 ± 0.076
17-hydroxyprogesterone 2.56 ± 0.44 1.94 ± 0.18 1.76 ± 0.13
Testosterone 3.14 ± 0.23 3.63 ± 0.23 2.85 ± 0.13
Progesterone 31.52 ± 2.96 34.98 ± 2.68 20.41 ± 1.02*
Values are expressed as mean ± SD
*ANOVA, P < 0.05 when compared with both CON and NC groups. CON: Blank Control; NC: Negative Control: 2#: CYP17 shRNA2#.
The relative expression levels of CYP17 mRNA 2 weeks  after lentivirus injection from six different replicates Figure 5
The relative expression levels of CYP17 mRNA 2 
weeks after lentivirus injection from six different rep-
licates. CON: Blank Control: NC: Negative Control: 2#: 
CYP17 shRNA2#. ANOVA, *P < 0.05, when compared with 
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